Boehringer Ingelheim

For media outside of the US, the UK & Canada only The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics1,2,3,4 Pooled safety data favour Pradaxa® treatment over warfarin and provide further reassurance1-4 The analysed … Read the full press release →

Ground-breaking ceremony for leading veterinary manufacturing plant in Taizhou/China Investment of 58 million Euro 200 job opportunities expected Taizhou, Jiangsu, China, and Ingelheim, Germany, 27-8-2013 — /EuropaWire/ — Today, the research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical … Read the full press release →

Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III study programme includes treatment naïve patients, including those ineligible for interferon and patients with liver cirrhosis The milestone coincides with … Read the full press release →

For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release →

Q2 2013 results: Adjusted net sales of $316.4 million (+3% CER) on growth in all regions; adjusted operating income of $83.4 million; adjusted diluted EPS of $0.27 per shareNew program authorized to repurchase up to $100 million in QIAGEN shares … Read the full press release →

2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with … Read the full press release →

Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release →

14-1-2013 — /europawire.eu/ — Gezielte Förderung von Wachstumsunternehmen belebt Wirtschaft und wertet Standort Österreich auf – 44 junge Firmen in der Gründungsphase mit 16,5 Millionen Euro unterstützt. Technologieorientierte Start-Ups wurden im Vorjahr aus Mitteln des Wirtschaftsministeriums stärker denn je zuvor bei … Read the full press release →

Announces it will begin remainder of pre-planned clinical trials for LY2605541 INDIANAPOLIS, IN, USA, and INGELHEIM, GERMANY, 11-1-2013 — /europawire.eu/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim International GmbH announced today they will adjust the scope of their … Read the full press release →